A sentence in the Discussion section caught my eye:
"We observed potential signals of clinical benefit for parkinsonism, cognition, hallucinations, sleep and RBD."
And it seems they are wasting no time. Enterin are also currently running a trial of orally-administered ENT-01 for Parkinson's disease dementia (NCT03938922):
A Study to Evaluate ENT- 1 for the Treatment of Parkinson's Disease Dementia - Full Text View - ClinicalTrials.gov